Premium
Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA)
Author(s) -
Inglis Sally C.,
McMurray John J.V.,
Böhm Michael,
Schaufelberger Maria,
Veldhuisen Dirk J.,
Lindberg Magnus,
Dunselman Peter,
Hjalmarson Åke,
Kjekshus John,
Waagstein Finn,
Wedel Hans,
Wikstrand John
Publication year - 2010
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1093/eurjhf/hfq070
Subject(s) - medicine , cardiology , heart failure , rosuvastatin , intermittent claudication , ejection fraction , myocardial infarction , hazard ratio , claudication , vascular disease , arterial disease , confidence interval
To examine the relationship between baseline intermittent claudication and outcomes in patients enrolled in the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA). Intermittent claudication is an independent predictor of worse outcome in coronary heart disease, but its prognostic importance in heart failure (HF) is unknown. Patients aged >or=60 years with NYHA class II-IV, low ejection fraction HF of ischaemic aetiology were enrolled in CORONA. Rosuvastatin did not reduce the primary outcome or all-cause mortality.